The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers

Waseem Kaialy, Gary P. Martin, Hassan Larhrib, Martyn D. Ticehurst, Ewa Kolosionek, Ali Nokhodchi

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The aim of this work was to investigate the mechanistic evaluation of physicochemical properties of new engineered lactose on aerosolisation performance of salbutamol sulphate (SS) delivered from dry powder inhaler (DPI). Different crystallised lactose particles were obtained from binary mixtures of butanol:acetone. The sieved fractions (63-90μm) of crystallised lactose were characterised in terms of size, shape, flowability, true density and aerosolisation performance (using multiple twin stage impinger (MSLI), Aerolizer ® inhaler device, and salbutamol sulphate as a model drug). Compared to commercial lactose, crystallised lactose particles were less elongated, covered with fine lactose particles, and had a rougher surface morphology. The crystallised lactose powders had a considerably lower bulk and tap density and poorer flow when compared to commercial lactose. Engineered carrier with better flow showed improved drug content homogeneity, reduced amounts of drug " deposited" on the inhaler device and throat, and a smaller drug aerodynamic diameter upon inhalation. Aerodynamic diameter of salbutamol sulphate increased as lactose aerodynamic diameter decreased (linear, R 2=0.9191) and/or as fine particle lactose content increased (linear, R 2=0.8653). Improved drug aerosolisation performance in the case of crystallised lactose particles was attributed to lower drug-carrier adhesion forces due to a rougher surface and higher fine particle content. In conclusion, this work proved that using binary combinations of solvents in crystallisation medium is vital in modification of the physicochemical and micromeritic properties of carriers to achieve a desirable aerosolisation performance from DPI formulations. Among all lactose samples, lactose particles crystallised from pure butanol generated the highest overall DPI formulations desirability.

Original languageEnglish
Pages (from-to)29-39
Number of pages11
JournalColloids and Surfaces B: Biointerfaces
Volume89
Issue number1
Early online date10 Sep 2011
DOIs
Publication statusPublished - 1 Jan 2012

Fingerprint

Dry Powder Inhalers
lactose
Albuterol
Lactose
Powders
Sulfates
sulfates
delivery
Physical properties
physical properties
Aerodynamics
Butenes
drugs
Binary mixtures
Acetone
aerodynamics
Surface morphology
Adhesion
Crystallization
Butanols

Cite this

Kaialy, Waseem ; Martin, Gary P. ; Larhrib, Hassan ; Ticehurst, Martyn D. ; Kolosionek, Ewa ; Nokhodchi, Ali. / The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers. In: Colloids and Surfaces B: Biointerfaces. 2012 ; Vol. 89, No. 1. pp. 29-39.
@article{baf98ddbdd4c4dafb6ef955e62a4a806,
title = "The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers",
abstract = "The aim of this work was to investigate the mechanistic evaluation of physicochemical properties of new engineered lactose on aerosolisation performance of salbutamol sulphate (SS) delivered from dry powder inhaler (DPI). Different crystallised lactose particles were obtained from binary mixtures of butanol:acetone. The sieved fractions (63-90μm) of crystallised lactose were characterised in terms of size, shape, flowability, true density and aerosolisation performance (using multiple twin stage impinger (MSLI), Aerolizer {\circledR} inhaler device, and salbutamol sulphate as a model drug). Compared to commercial lactose, crystallised lactose particles were less elongated, covered with fine lactose particles, and had a rougher surface morphology. The crystallised lactose powders had a considerably lower bulk and tap density and poorer flow when compared to commercial lactose. Engineered carrier with better flow showed improved drug content homogeneity, reduced amounts of drug {"} deposited{"} on the inhaler device and throat, and a smaller drug aerodynamic diameter upon inhalation. Aerodynamic diameter of salbutamol sulphate increased as lactose aerodynamic diameter decreased (linear, R 2=0.9191) and/or as fine particle lactose content increased (linear, R 2=0.8653). Improved drug aerosolisation performance in the case of crystallised lactose particles was attributed to lower drug-carrier adhesion forces due to a rougher surface and higher fine particle content. In conclusion, this work proved that using binary combinations of solvents in crystallisation medium is vital in modification of the physicochemical and micromeritic properties of carriers to achieve a desirable aerosolisation performance from DPI formulations. Among all lactose samples, lactose particles crystallised from pure butanol generated the highest overall DPI formulations desirability.",
keywords = "Carrier, Dry powder inhaler, Inhalation efficiency, Lactose crystallisation, Morphology, Non-solvent",
author = "Waseem Kaialy and Martin, {Gary P.} and Hassan Larhrib and Ticehurst, {Martyn D.} and Ewa Kolosionek and Ali Nokhodchi",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.colsurfb.2011.08.019",
language = "English",
volume = "89",
pages = "29--39",
journal = "Colloids and Surfaces B: Biointerfaces",
issn = "0927-7765",
publisher = "Elsevier",
number = "1",

}

The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers. / Kaialy, Waseem; Martin, Gary P.; Larhrib, Hassan; Ticehurst, Martyn D.; Kolosionek, Ewa; Nokhodchi, Ali.

In: Colloids and Surfaces B: Biointerfaces, Vol. 89, No. 1, 01.01.2012, p. 29-39.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers

AU - Kaialy, Waseem

AU - Martin, Gary P.

AU - Larhrib, Hassan

AU - Ticehurst, Martyn D.

AU - Kolosionek, Ewa

AU - Nokhodchi, Ali

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The aim of this work was to investigate the mechanistic evaluation of physicochemical properties of new engineered lactose on aerosolisation performance of salbutamol sulphate (SS) delivered from dry powder inhaler (DPI). Different crystallised lactose particles were obtained from binary mixtures of butanol:acetone. The sieved fractions (63-90μm) of crystallised lactose were characterised in terms of size, shape, flowability, true density and aerosolisation performance (using multiple twin stage impinger (MSLI), Aerolizer ® inhaler device, and salbutamol sulphate as a model drug). Compared to commercial lactose, crystallised lactose particles were less elongated, covered with fine lactose particles, and had a rougher surface morphology. The crystallised lactose powders had a considerably lower bulk and tap density and poorer flow when compared to commercial lactose. Engineered carrier with better flow showed improved drug content homogeneity, reduced amounts of drug " deposited" on the inhaler device and throat, and a smaller drug aerodynamic diameter upon inhalation. Aerodynamic diameter of salbutamol sulphate increased as lactose aerodynamic diameter decreased (linear, R 2=0.9191) and/or as fine particle lactose content increased (linear, R 2=0.8653). Improved drug aerosolisation performance in the case of crystallised lactose particles was attributed to lower drug-carrier adhesion forces due to a rougher surface and higher fine particle content. In conclusion, this work proved that using binary combinations of solvents in crystallisation medium is vital in modification of the physicochemical and micromeritic properties of carriers to achieve a desirable aerosolisation performance from DPI formulations. Among all lactose samples, lactose particles crystallised from pure butanol generated the highest overall DPI formulations desirability.

AB - The aim of this work was to investigate the mechanistic evaluation of physicochemical properties of new engineered lactose on aerosolisation performance of salbutamol sulphate (SS) delivered from dry powder inhaler (DPI). Different crystallised lactose particles were obtained from binary mixtures of butanol:acetone. The sieved fractions (63-90μm) of crystallised lactose were characterised in terms of size, shape, flowability, true density and aerosolisation performance (using multiple twin stage impinger (MSLI), Aerolizer ® inhaler device, and salbutamol sulphate as a model drug). Compared to commercial lactose, crystallised lactose particles were less elongated, covered with fine lactose particles, and had a rougher surface morphology. The crystallised lactose powders had a considerably lower bulk and tap density and poorer flow when compared to commercial lactose. Engineered carrier with better flow showed improved drug content homogeneity, reduced amounts of drug " deposited" on the inhaler device and throat, and a smaller drug aerodynamic diameter upon inhalation. Aerodynamic diameter of salbutamol sulphate increased as lactose aerodynamic diameter decreased (linear, R 2=0.9191) and/or as fine particle lactose content increased (linear, R 2=0.8653). Improved drug aerosolisation performance in the case of crystallised lactose particles was attributed to lower drug-carrier adhesion forces due to a rougher surface and higher fine particle content. In conclusion, this work proved that using binary combinations of solvents in crystallisation medium is vital in modification of the physicochemical and micromeritic properties of carriers to achieve a desirable aerosolisation performance from DPI formulations. Among all lactose samples, lactose particles crystallised from pure butanol generated the highest overall DPI formulations desirability.

KW - Carrier

KW - Dry powder inhaler

KW - Inhalation efficiency

KW - Lactose crystallisation

KW - Morphology

KW - Non-solvent

UR - http://www.scopus.com/inward/record.url?scp=80054988878&partnerID=8YFLogxK

U2 - 10.1016/j.colsurfb.2011.08.019

DO - 10.1016/j.colsurfb.2011.08.019

M3 - Article

VL - 89

SP - 29

EP - 39

JO - Colloids and Surfaces B: Biointerfaces

JF - Colloids and Surfaces B: Biointerfaces

SN - 0927-7765

IS - 1

ER -